Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Tuesday, 9 January 2018

Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2017

Essilor International    

Published: 18:00 CET 09-01-2018 /GlobeNewswire /Source: Essilor International / : EI /ISIN: FR0000121667


Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2017

 

(Pursuant to Article L.233-8 II of the French Commercial Code
and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)

 

Charenton-le-Pont, France (January 9, 2018 - 6.00 p.m.) - As of December 31, 2017, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

 

December 31, 2017

Shares outstanding

219,125,439

Exercisable voting rights

234,699,753

Total voting rights, based on all outstanding shares,
including shares stripped of their voting rights*

236,044,180

(*) Shares held by the Company.

 

 

About Essilor

Essilor International (Compagnie Générale d'Optique) ("Essilor") is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, EyezenTM, Xperio®, Foster Grant®, BolonTM and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of more than €7.1 billion in 2016 and employs approximately 64,000 people worldwide. It markets its products in more than 100 countries and has 33 plants, 490 prescription laboratories and edging facilities, as well as 5 research and development centers around the world (as of December 31, 2016). For more information, please visit www.essilor.com.

The Essilor International share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. 

Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

 

------------------------

 

Investor Relations and Financial Communications

Phone: +33 (0)1 49 77 42 16




PDF Version of the news release



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Essilor International, 147 rue de Paris, Charenton-Le-Pont FR-94220, France
If you would like to unsubscribe and stop receiving these e-mails click here.